Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration

被引:4
作者
Bellmann, R. [1 ,2 ]
Falkensammer, G. [3 ]
Seger, C. [3 ]
Weiler, S. [2 ]
Kountchev, J. [1 ]
Joannidis, M. [1 ]
机构
[1] Innsbruck Med Univ, Dept Internal Med 1, Intens Care Unit, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Inflammat Res Lab, Clin Pharmacokinet Unit, A-6020 Innsbruck, Austria
[3] Innsbruck Gen Hosp, Cent Inst Med & Chem Lab Diagnost, Innsbruck, Austria
关键词
glycopeptide antibiotics; continuous renal replacement therapy; drug monitoring; hemofilter clearance; RENAL REPLACEMENT THERAPY; ARTERIOVENOUS HEMOFILTRATION; DOSAGE; SERUM; ELIMINATION; REMOVAL;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics of teicoplanin (TP) was assessed in critically ill patients on continuous veno-venous hemofiltration (CVVH), in eleven patients, after the first dose and in another four after repeated administration. The TP peak concentration amounted to 55.44 +/- 15.90 mu g/ml and 81.28 +/- 28.55 mu g/ml (mean +/- SD), the trough concentration 6.4 +/- 1.7 mu g/ml and 21.3 +/- 5.0 mu g/ml, the half-life 15.7 +/- 5.7 and 35.1 +/- 12.3 h, the apparent volume of distribution 0.84 +/- 0.22 and 0.48 +/- 0.09 l/kg and the TP clearance 39 +/- 12 and 11 +/- 4 ml/h/kg after the first close and after repeated administration, respectively. The mean sieving coefficient of TP was 0.15. After a 1,200 mg loading dose, daily maintenance doses of 600 - 1,800 mg were required for achieving trough levels of 15 - 25 mu g/ml. Therapeutic drug monitoring is indispensable during CVVH because of a considerable variability of TP pharmacokinetics.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 23 条
[1]  
Bellmann R, 2002, INT J CLIN PHARM TH, V40, P142
[2]  
BOHLER J, 1999, KIDNEY INT S, V72, P24
[3]   Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing [J].
Bouman, Catherine S. C. ;
Van Kan, Hendrikus J. M. ;
Koopmans, Richard P. ;
Korevaar, JohannaC. ;
Schultz, Marcus J. ;
Vroom, Margreeth B. .
INTENSIVE CARE MEDICINE, 2006, 32 (12) :2013-2019
[4]   PHARMACOKINETICS AND TOLERABILITY OF TEICOPLANIN IN HEALTHY-VOLUNTEERS AFTER SINGLE INCREASING DOSES [J].
DELFAVERO, A ;
PATOIA, L ;
ROSINA, R ;
BUNIVA, G ;
DANESE, A ;
BERNAREGGI, A ;
MOLINI, E ;
CAVENAGHI, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (12) :2551-2557
[5]   Safety and efficacy of glycopeptide antibiotics [J].
Finch, RG ;
Eliopoulos, GM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 :5-13
[6]  
GOLPER TA, 1985, INT J ARTIF ORGANS, V8, P307
[7]   Comparison of pharmacokinetics of individual teicoplanin components in patients [J].
Hanada, Kazuhiko ;
Ikari, Shingo ;
Koukaki, Yukari ;
Utena, Ayako ;
Yimura, Toshimi ;
Hamano, Kunitoshi ;
Ariki, Hiromune ;
Masuhara, Keiso ;
Ogata, Hiroyasu .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (05) :952-954
[8]   Teicoplanin therapy for Staphylococcus aureus septicaemia:: relationship between pre-dose serum concentrations and outcome [J].
Harding, I ;
MacGowan, AP ;
White, LO ;
Darley, ESR ;
Reed, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :835-841
[9]   INFLUENCE OF ARTERIOVENOUS HEMOFILTRATION ON TEICOPLANIN ELIMINATION [J].
HILLAIREBUYS, D ;
PEYRIERE, H ;
LOBJOIE, E ;
BRES, J ;
OSSART, M ;
DESPAUX, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (01) :95-97
[10]   Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration [J].
Kroh, UF ;
Lennartz, H ;
Edwards, DJ ;
Stoeckel, K .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (12) :1114-1119